Artivion Inc
NYSE:AORT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jilin Jlu Communication Design Institute Co Ltd
SZSE:300597
|
CN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (29.7), the stock would be worth $27.51 (25% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 39.5 | $36.56 |
0%
|
| 3-Year Average | 29.7 | $27.51 |
-25%
|
| 5-Year Average | 28.9 | $26.73 |
-27%
|
| Industry Average | 12.9 | $11.92 |
-67%
|
| Country Average | 14.4 | $13.28 |
-64%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$2B
|
/ |
Jan 2026
$49.2m
|
= |
|
|
$2B
|
/ |
Dec 2026
$106.5m
|
= |
|
|
$2B
|
/ |
Dec 2027
$127.7m
|
= |
|
|
$2B
|
/ |
Dec 2028
$152.2m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Artivion Inc
NYSE:AORT
|
1.7B USD | 39.5 | 179.3 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161B USD | 13.9 | 25.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
160.3B USD | 45.6 | 60.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.2B USD | 19.8 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.2B USD | 12.8 | 23.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.3B USD | 19.5 | 32.9 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
41.6B EUR | 11.1 | 19.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 24 | 44 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.4B USD | 30.7 | 43.4 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.6B USD | 10 | 25.1 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.9B USD | 11.2 | 15.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Artivion Inc
Glance View
In the heart of the biomedical landscape, Artivion Inc. emerges as a company fervently dedicated to extending and saving lives through advanced medical technologies. It is a principal innovator and supplier in cardiac and vascular surgery, carving its niche by providing unique products that serve critical therapeutic needs. Initially branded as CryoLife, the company redefined its mission and vision under the Artivion name post a strategic transformation, focusing on strategically enhancing its product portfolio. It crafts precision-engineered prosthetic heart valves, notably the On-X mechanical valve, which is renowned for its exceptional long-term durability and performance in reducing the need for anticoagulation therapy. Through its relentless innovation, Artivion ensures that its offerings are not only of high quality but also cost-effective, thereby widening the accessibility to life-saving technologies. This commitment to quality is underscored by their rigorous research and development efforts and regulatory compliance, ensuring every product meets global medical standards. Artivion's revenue engine is driven largely by its cardiovascular implantables and bioprosthetics used in vascular surgery, alongside tissue processing services that provide mitral, aortic, and pulmonary cardiac valves. By coupling advanced materials and sophisticated design, the organization enhances its presence in the global cardiovascular industry—serving hospitals, physicians, and patients alike. Its products are distributed through a combination of direct sales and distributor partnerships, broadening its geographical market presence from the United States to Europe, Asia, and beyond. Artivion stands not only as a supplier but as a strategic partner to clinicians, extending support and education to ensure optimal patient outcomes. Its strategic prowess in the competitive med-tech arena is an intricate mosaic of innovation, operational excellence, and a keen awareness of the pressing health challenges that afflict the global population. Through these concerted efforts, Artivion not only sustains its growth and shareholder value but continues its mission to improve life expectancy and quality around the world.